Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
The Science of the Total Environment|November 11, 2023
Dryness stress weakens the sustainability of global vegetation coolingZilin Li, Xiaoyong Bai, Qiu Tan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsKatie Chon, Erin Larkins, Somak Chatterjee, et al.Journal of Medicinal Chemistry|June 13, 2017
Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein InteractionHacer Karatas, Yangbing Li, Liu Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2020
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung CancerSonia Singh, Adnan A Jaigirdar, Flora Mulkey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis ReviewAbigail L Koch, Paz J Vellanki, Nicole Drezner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid TumorsElizabeth S Duke, Diana Bradford, Michelle Marcovitz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or FusionsDiana Bradford, Erin Larkins, Sirisha L Mushti, et al.Pageof 5